eligibility_summary
Adults ≥18, ECOG 0–2, with measurable DLBCL/NHL/HGBCL relapsed/refractory after CAR‑T (PD anytime or PR/SD at 3 mo). Prior loncastuximab allowed if stopped in CR/PR. Adequate organ/hematologic function, negative pregnancy test, effective contraception. Exclude: hypersensitivity, pregnancy/lactation, active second malignancy, CNS disease, tumor >10 cm, significant effusions, major comorbidities, autoimmune disease, SJS/TEN, HIV/HBV/HCV needing treatment, recent therapy/investigational drug/live vaccine, unresolved ≥G2 toxicities.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Loncastuximab tesirine, an antibody–drug conjugate (ADC). Type/mechanism: an anti‑CD19 monoclonal antibody (IgG1) linked to a pyrrolobenzodiazepine (PBD) dimer cytotoxic payload. It binds CD19 on B cells, is internalized, and releases PBD that forms DNA interstrand crosslinks, causing irreparable DNA damage and apoptosis, Fc-mediated effector functions may contribute. Targets: CD19-expressing malignant B cells in DLBCL/HGBCL, engaging the CD19/B‑cell receptor axis and triggering DNA damage response pathways. Population: post–CAR‑T failure.